세계의 마이크로바이옴 진단 시장 : 제품별, 기술별, 샘플별, 용도별 - 예측(-2028년)
Microbiome Diagnostics Market by Product (Kits & Reagents, Instruments), Technology (16s rRNA Sequencing, Shot Gun Metagenomics, Metatranscriptomics), Sample (Fecal, Saliva, Skin), Application (GI, Metabolic Disorders) - Global Forecast to 2028
상품코드:1442280
리서치사:MarketsandMarkets
발행일:2024년 02월
페이지 정보:영문 179 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
세계 마이크로바이옴 진단 시장 규모는 2023년 1억 4,600만 달러에서 예측 기간 동안 15.5%의 연평균 복합 성장률(CAGR)을 기록하며 2028년에는 3억 달러 규모로 성장할 것으로 예상됩니다.
마이크로바이옴 진단에 대한 인식 개선, 개인 맞춤형 의료에 대한 수요 증가, 질병 발생률 증가 등의 요인으로 인해 이 시장의 성장이 촉진되고 있습니다.
조사 범위
조사 대상년도
2022-2028년
기준년도
2023년
예측 기간
2023-2028년
검토 단위
금액(USD)
부문
제품, 기술, 샘플, 용도, 최종사용자, 지역
대상 지역
북미, 유럽, 아시아태평양 및 기타 지역
제품별로는 시약 및 키트가 가장 큰 점유율을 보이고 있습니다. 성장의 주요 원동력은 마이크로바이옴 기반 진단 절차에서 시약&키트의 반복적인 사용과 전 세계적으로 수행되는 마이크로바이옴 기반 검사 증가입니다. 또한, 효율적인 결과와 진단 정확도를 제공하는 우수한 시약&키트의 출시도 이 부문의 성장에 기여하고 있습니다.
기술별로는 16S rRNA 시퀀싱 부문이 예측 기간 동안 큰 성장률을 보일 것으로 예상됩니다. 모세관 시퀀싱이나 PCR 기반 접근법에 비해 16S rRNA 시퀀싱은 배양이 필요 없는 기술로, 연구자들은 샘플 내 전체 미생물 군집을 분석할 수 있으며, NGS 기반 16S rRNA 시퀀싱은 한 번의 시퀀싱 실행으로 많은 수의 샘플을 조합할 수 있기 때문에 샘플을 한 번의 시퀀싱 실행으로 결합할 수 있기 때문에 기존 방법으로는 찾을 수 없는 박테리아 균주를 식별할 수 있는 비용 효율적인 방법입니다.
지역별로는 아시아태평양이 가장 큰 성장세를 보이고 있습니다. 이 지역의 높은 성장의 배경에는 아시아 국가들의 질병 증가, 마이크로바이옴 연구 활동의 활성화가 있습니다.
세계 마이크로바이옴 진단(Microbiome Diagnostics) 시장을 조사했으며, 시장 개요, 시장 영향요인 및 시장 기회 분석, 기술 및 특허 동향, 규제 환경, 사례연구, 시장 규모 추이 및 예측, 각종 부문별/지역별 상세 분석, 경쟁 구도, 주요 기업 프로파일 등의 정보를 전해드립니다.
목차
제1장 서론
제2장 조사 방법
제3장 주요 요약
제4장 프리미엄 인사이트
제5장 시장 개요
시장 역학
성장 촉진요인
성장 억제요인
기회
과제
밸류체인 분석
공급망 분석
Porter의 Five Forces 분석
주요 이해관계자와 구입 기준
규제 상황
생태계 분석
특허 분석
주요 컨퍼런스 및 이벤트
가격 분석
고객의 비즈니스에 영향을 미치는 동향/파괴적 변화
기술 분석
무역 분석
제6장 마이크로바이옴 진단 시장 : 제품별
키트 및 시약
기기
제7장 마이크로바이옴 진단 시장 : 기술별
16s rRNA 시퀀싱
샷건 메타유전체학
METATRANSCRIPTOMICS
기타
제8장 마이크로바이옴 진단 시장 : 샘플별
대변
타액
피부
기타
제9장 마이크로바이옴 진단 시장 : 용도별
잴병 진단 용도
위장 장애
대사장애증
기타
연구 용도
제10장 마이크로바이옴 진단 시장 : 최종사용자별
병원
연구기관
제약 및 바이오테크놀러지 기업
제11장 마이크로바이옴 진단 시장 : 지역별
북미
유럽
아시아태평양
기타 지역
제12장 경쟁 구도
개요
주요 기업의 전략/유력 기업
매출 분석
시장 점유율 분석
기업 평가 매트릭스
신규 기업/중소기업 평가 매트릭스
경쟁 시나리오·동향
제13장 기업 개요
주요 기업
GENETIC ANALYSIS AS
DNA GENOTEK(ORASURE TECHNOLOGIES, INC.)
MICROBA LIFE SCIENCES
ILLUMINA INC.
OXFORD NANOPORE TECHNOLOGIES, PLC
BIOME OXFORD LTD.
VIENNALAB DIAGNOSTICS GMBH
METABIOMICS
VIOME LIFE SCIENCES
LUXIA SCIENTIFIC
SUN GENOMICS
ATLAS BIOMED
QUANTBIOME, INC.(DBA OMBRE)
BECTON, DICKINSON AND COMPANY
DAYTWO
기타 기업
MICRONOMA
TERAOMICS S.L.
FLIGHTPATH BIOSCIENCES
MICROBIOME RESEARCH PVT. LTD.
ORIGIN SCIENCES
LEUCINE RICH BIO PRIVATE LIMITED
DECODE AGE
EVVY
ALPHABIOMICS, LTD.
GOODGUT
제14장 부록
LSH
영문 목차
영문목차
The global microbiome diagnostics market is valued at an estimated USD 146 million in 2023 and is projected to reach USD 300 million by 2028, at a CAGR of 15.5% during the forecast period. Market growth is driven by factors such as increasing awareness of microbiome diagnostics, increasing demand of personalize medicine and increasing incidences of diseases.
Scope of the Report
Years Considered for the Study
2022-2028
Base Year
2023
Forecast Period
2023-2028
Units Considered
Value (USD) Million
Segments
Product, Technology, Sample, Application, End User, and Region
Regions covered
North America, Europe, Asia Pacific, Rest of the World
"The reagents & kits to register the largest share of the microbiome diagnostics market, by product."
The global microbiome diagnostics market is segmented into reagents & kits and instruments on product. Market growth is largely driven by the repetitive use of reagents & kits for microbiome-based diagnostic procedures coupled with the increase in the volume of microbiome-based tests conducted worldwide. Moreover, the availability of better reagents & kits that offer efficient results and precision in diagnosis attributes to their growing requirement resulting in growth of the segment.
"16s rRNA sequencing segment to grow at a considerable rate among technology during the forecast period."
The microbiome diagnostics market is segmented into 16s rRNA sequencing, shotgun metagenomics, metatranscriptomics and other technologies. As compared to capillary sequencing or PCR-based approaches, 16S rRNA sequencing is a culture-free technique that enables researchers to analyze the entire microbial community within a sample. Due to its ability to combine many samples in a sequencing run, NGS-based 16S rRNA sequencing is a cost-effective technique for identifying bacterial strains that may not be found using traditional methods.
"Research application segment accounted for the largest share in the microbiome diagnostics market, by application."
The global microbiome diagnostics market is segmented into research application, disease diagnostic application. The application segment of disease diagnostic application accounted for a considerable share in 2022, primarily due to rising prevalence of diseases.
"Asia Pacific: The fastest-growing region in the microbiome diagnostics market."
The global microbiome diagnostics market is segmented into five regions - North America, Europe, the Asia Pacific, Rest of the World. The Asia Pacific region is expected to grow at the highest rate during the forecast period in the microbiome-based diagnostics market. The high growth in the region is due to the increasing incidences of diseases, increasing microbiome research activities in Asian countries.
The break-up of the profile of primary participants in the microbiome diagnostics market:
By Company Type: Tier 1 - 55%, Tier 2 - 40%, and Tier 3 - 5%
By Designation: C-level - 37%, D-level - 48%, and Others - 15%
By Region: North America - 56%, Europe - 20%, Asia Pacific - 17%, Rest of the World- 7%,
The key players in this market are DNA Genotek (Canada), Invivo Healthcare (UK), Microba Life Sciences (US), Genetic Analysis AS (Norway), Metabiomics (US), Teraomics (US), Becton, Dickinson and Company (US), BioMe Oxford Ltd (UK), Viennalab Diagnostics (Austria), Viome Life Sciences, Inc. (US), Luxia Scientific (France), DayTwo (US), Sun Genomics (US), Atlas Biomed (UK), Quantbiome, Inc. (US), GoodGut (US), Micronoma (US), FlightPath Biosciences (US), and Microbiome Research Pvt. Ltd. (India)
Research Coverage:
This research report categorizes the microbiome diagnostics market by product (reagents & kits and instruments), sample (feces, saliva, skin and other sample), technology (16s rRNA sequencing, shotgun metagenomics, metatranscriptomics and other technology), application (research application, disease diagnosis and monitoring), end user (research institutes, pharmaceutical and biotechnology companies, hospitals and other end user), and region (North America, Europe, Asia Pacific, Rest of the World). The scope of the report covers detailed information regarding the major factors, such as drivers, opportunities, and challenges, influencing the growth of the microbiome diagnostics market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products offered, key strategies, acquisitions, and partnerships. New product launches and approvals, and recent developments associated with the microbiome diagnostics market. This report covers the competitive analysis of upcoming startups in the microbiome-based diagnostics market ecosystem.
Reasons to buy this report:
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall microbiome diagnostics market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.
The report provides insights on the following pointers:
Analysis of key drivers (The collaborative efforts between the microbiome industry and academia for microbiome research and the growing demand for personalized medicine, growing awareness about the importance of the human microbiome diagnostics, rising incidences of disease), opportunities (Increased collaboration of key players and small innovative companies to work on new microbiome technologies), and challenges (Adverse impact of complex regulatory policies on commercialization of microbiome ) influencing the growth of the microbiome-based market
Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the microbiome diagnostics market.
Market Development: Comprehensive information about lucrative markets - the report analyses the microbiome diagnostics market across varied regions.
Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the microbiome diagnostics market
Competitive Assessment: In-depth assessment of market shares, growth strategies and product offerings of leading players like DNA Genotek (Canada), Invivo Healthcare (UK), Microba Life Sciences (US), and Genetic Analysis AS (Norway)among others in the microbiome-based diagnostics market strategies.
(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)**
13.1.1 GENETIC ANALYSIS AS
TABLE 138 GENETIC ANALYSIS AS: COMPANY OVERVIEW
FIGURE 33 GENETIC ANALYSIS AS: COMPANY SNAPSHOT (2022)
13.1.2 DNA GENOTEK (ORASURE TECHNOLOGIES, INC.)
TABLE 139 DNA GENOTEK: COMPANY OVERVIEW
FIGURE 34 ORASURE TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2022)
13.1.3 MICROBA LIFE SCIENCES
TABLE 140 MICROBA LIFE SCIENCES: COMPANY OVERVIEW
FIGURE 35 MICROBA LIFE SCIENCES: COMPANY SNAPSHOT (2023)
13.1.4 ILLUMINA INC.
TABLE 141 ILLUMINA INC.: COMPANY OVERVIEW
FIGURE 36 ILLUMINA INC.: COMPANY SNAPSHOT (2022)
13.1.5 OXFORD NANOPORE TECHNOLOGIES, PLC
TABLE 142 OXFORD NANOPORE TECHNOLOGIES, PLC: COMPANY OVERVIEW
FIGURE 37 OXFORD NANOPORE TECHNOLOGIES, PLC.: COMPANY SNAPSHOT (2022)
13.1.6 BIOME OXFORD LTD.
TABLE 143 BIOME OXFORD LTD.: COMPANY OVERVIEW
13.1.7 VIENNALAB DIAGNOSTICS GMBH
TABLE 144 VIENNALAB DIAGNOSTICS GMBH: COMPANY OVERVIEW
13.1.8 METABIOMICS (A SUBSIDIARY OF PRESCIENT MEDICINE HOLDINGS, INC.)
TABLE 145 METABIOMICS: COMPANY OVERVIEW
13.1.9 VIOME LIFE SCIENCES
TABLE 146 VIOME LIFE SCIENCES: COMPANY OVERVIEW
13.1.10 LUXIA SCIENTIFIC
TABLE 147 LUXIA SCIENTIFIC: COMPANY OVERVIEW
13.1.11 SUN GENOMICS
TABLE 148 SUN GENOMICS: COMPANY OVERVIEW
13.1.12 ATLAS BIOMED
TABLE 149 ATLAS BIOMED: COMPANY OVERVIEW
13.1.13 QUANTBIOME, INC. (DBA OMBRE)
TABLE 150 QUANTBIOME, INC.: COMPANY OVERVIEW
13.1.14 BECTON, DICKINSON AND COMPANY
TABLE 151 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW
FIGURE 38 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2022)
13.1.15 DAYTWO
TABLE 152 DAYTWO: COMPANY OVERVIEW
*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.
